ZYNE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 okt 2023 @ 22:00):

Stats
Dagens volum	861 742
Gjennomsnittsvolum	1.04M
Markedsverdi	70.12M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.646
ATR14	$0.0400 (3.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-10	Jones Kenneth T	Buy	30 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	40 520	Common Stock
2023-10-10	Jones Kenneth T	Sell	75 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	21 250	Stock Option (Right to Buy)
2023-10-10	Stephenson Pamela	Sell	27 954	Common Stock

INSIDER POWER
-52.80
Last 100 transactions
Buy: 1 916 312 \| Sell: 5 402 740

Volum Korrelasjon

Lang: 0.26 (neutral)

Kort: -0.55 (weak negative)

Signal:(58.623) Neutral

Zynerba Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
FULT	0.896
BUSE	0.856
CBSH	0.852
GOODM	0.85
CMCT	0.847
CCNE	0.847
COLB	0.847
FBIZ	0.844
AMTB	0.841
INTZ	0.839

10 Mest negative korrelasjoner
AMRB	-0.841
LMRKN	-0.834
LWAC	-0.817
RAVN	-0.811
SRAC	-0.811
CALT	-0.809
OBT	-0.809
LONE	-0.806

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Zynerba Pharmaceuticals Korrelasjon - Valuta/Råvare

0.23
( neutral )

0.48
( neutral )

0.77
( moderate )

0.67
( moderate )

-0.42
( neutral )

-0.31
( neutral )

Zynerba Pharmaceuticals Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.820

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.820

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.950

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.900

Financial Reports:

No articles found.

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.